THERAPY AND PREVENTION OF DIARRHEA ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION DURING THE COVID-19 PANDEMIA
The review summarizes the materials of international clinical guidelines and the results of clinical trials on the use of antibiotics and biological therapy for the treatment and prophylaxis of diarrhea associated with Clostridium difficile infection in the conditions of the COVID-19 pandemia. A requirement necessary for the successful treatment of the first episode of diarrhea associated with Clostridium difficile infection is the withdrawal of previously prescribed antibiotics and timely administration of the standard etiotropic therapy for 10 days (vancomycin, fidaxomicin, or metronidazole, depending on the severity of the case). In recurrent episodes of pseudomembranous colitis, the standard therapy (vancomycin, fidaxomicin) is provided in a tapered/pulsed regimen for up to 5-8 weeks with gradual reduction of the dose and frequency of administration.